Imagine printing a replacement heart valve using a patient's own cells instead of using a plastic part or a donor animal valve. Because it is made from the person's own tissue, the body doesn't fight it, and it can grow with the patient. This means children wouldn't need multiple dangerous open-heart surgeries as they get older.
Current heart valves fail after 10 years and do not grow with children, forcing pediatric patients to undergo 4-5 risky surgeries before adulthood.
A patient-specific autologous heart valve created using medical imaging and 3D printing techniques.
If you are a manufacturer dealing with the short 10-year lifespan of current biological valves — this project developed an autologous valve that lasts a lifetime. This removes the need for repeat surgeries and eliminates tissue rejection.
If you are a hospital dealing with high ICU occupancy and frequent re-operations for pediatric patients — this project developed a one-time treatment that could save €16B/year in Europe by shortening hospital stays.
If you are a biotech firm dealing with the lack of pediatric-specific heart valve products — this project developed a technique using medical imaging and 3D printing to create patient-specific tissue valves.
Based on available project data, the adoption of this technology could potentially save €16B/year in Europe by reducing ICU occupancy and shortening hospital stays.
Based on available project data, the process uses medical imaging and 3D printing techniques to create patient-specific valves, though specific industrial scaling metrics are not provided.
Based on available project data, the technology is developed by GrownValve GmbH, but specific patent or licensing details are not listed in the summary.
It aims to replace the current cycle where pediatric patients may endure 4-5 surgeries between 0-18 years of age with a one-time, lifelong solution.
The valve is crafted using the patient's own tissue via 3D printing and medical imaging to ensure compatibility and optimal function.
The project is led by a single German SME, GrownValve GmbH, with a 100% industry ratio. This indicates a highly focused, commercially-driven effort without the dilution of academic partners, suggesting the technology is being developed specifically for market entry.
Contact GrownValve GmbH in Germany for licensing and partnership inquiries.
Contact us to explore partnership opportunities with GrownValve GmbH.
